KYTX logo

Kyverna Therapeutics (KYTX) Company Overview

Profile

Full Name:

Kyverna Therapeutics, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

February 9, 2024

Indexes:

Not included

Description:

Kyverna Therapeutics focuses on developing innovative cell therapies to treat autoimmune diseases. The company uses advanced technology to engineer T cells, aiming to provide targeted and effective treatments that can improve patient outcomes and quality of life.

Events Calendar

Earnings

Next earnings date:

May 30, 2025

Recent quarterly earnings:

Nov 13, 2024

Recent annual earnings:

N/A
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

Nov 20, 24 HC Wainwright & Co.
Neutral
Nov 15, 24 Wells Fargo
Overweight
Oct 10, 24 UBS
Buy
Sep 19, 24 HC Wainwright & Co.
Neutral
Aug 15, 24 HC Wainwright & Co.
Neutral
Jul 31, 24 JP Morgan
Overweight
Jul 16, 24 HC Wainwright & Co.
Neutral
Jul 3, 24 HC Wainwright & Co.
Neutral
Mar 4, 24 Morgan Stanley
Overweight
Mar 4, 24 JP Morgan
Overweight

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

FAQ

  • What is the ticker symbol for Kyverna Therapeutics?
  • Does Kyverna Therapeutics pay dividends?
  • What sector is Kyverna Therapeutics in?
  • What industry is Kyverna Therapeutics in?
  • What country is Kyverna Therapeutics based in?
  • When did Kyverna Therapeutics go public?
  • Is Kyverna Therapeutics in the S&P 500?
  • Is Kyverna Therapeutics in the NASDAQ 100?
  • Is Kyverna Therapeutics in the Dow Jones?
  • When was Kyverna Therapeutics's last earnings report?
  • When does Kyverna Therapeutics report earnings?
  • Should I buy Kyverna Therapeutics stock now?

What is the ticker symbol for Kyverna Therapeutics?

The ticker symbol for Kyverna Therapeutics is NASDAQ:KYTX

Does Kyverna Therapeutics pay dividends?

No, Kyverna Therapeutics does not pay dividends

What sector is Kyverna Therapeutics in?

Kyverna Therapeutics is in the Healthcare sector

What industry is Kyverna Therapeutics in?

Kyverna Therapeutics is in the Biotechnology industry

What country is Kyverna Therapeutics based in?

Kyverna Therapeutics is headquartered in United States

When did Kyverna Therapeutics go public?

Kyverna Therapeutics's initial public offering (IPO) was on February 9, 2024

Is Kyverna Therapeutics in the S&P 500?

No, Kyverna Therapeutics is not included in the S&P 500 index

Is Kyverna Therapeutics in the NASDAQ 100?

No, Kyverna Therapeutics is not included in the NASDAQ 100 index

Is Kyverna Therapeutics in the Dow Jones?

No, Kyverna Therapeutics is not included in the Dow Jones index

When was Kyverna Therapeutics's last earnings report?

Kyverna Therapeutics's most recent earnings report was on Nov 13, 2024

When does Kyverna Therapeutics report earnings?

The next expected earnings date for Kyverna Therapeutics is May 30, 2025

Should I buy Kyverna Therapeutics stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions